ATYR · aTyr Pharma, Inc.

aTyr Pharma disclosed preliminary unaudited cash position of $68.3 million as of March 31, 2026, providing visibility into its liquidity to support ongoing operations and development activities. This balance sheet snapshot is critical for investors tracking runway amid clinical-stage biotech expenses. The core event centers on a regulatory update following a Type C FDA meeting reviewing Phase 3 EFZO-FIT™ results, which missed its primary endpoint but showed safety consistency and benefits on quality-of-life measures. FDA supported FVC as a direct functional measure and KSQ-Lung for patient-reported outcomes, with recommendations for further validation including wheezing/cough severity and anchors. Responding to this feedback, aTyr plans a refined Phase 3 (C-006) targeting a homogenous restrictive lung disease population (FVC percent predicted ≤80%), where prior data showed 124 ml FVC improvement over placebo. Dosing intensifies to Q3W from Q4W, deemed reasonable by FDA clinically with enhanced safety measures like anti-synthetase syndrome surveillance and a data safety monitoring committee. The 54-week, 372-patient global trial maintains stable background therapy, positioning efzofitimod for potential approval in a ~38k-62k US patient market subset of pulmonary sarcoidosis without advanced fibrosis. IND submission in June 2026 marks near-term catalyst, balancing prior trial learnings with FDA alignment to de-risk the program.